| Value | ₹5,000 Cr |
|---|
NSE filing, NSE: ULTRACEMCO. Summary written from the filing by ALFA Finder's alert engine.
UltraTech Cement Ltd: key numbers
- Share price
- ₹11,045.00
- Market cap
- ₹3,25,473 Cr
- Revenue (annual)
- ₹88,512 Cr
- Net profit (annual)
- ₹8,166 Cr
- P/E (TTM)
- 37.0×Sector 32.2×
- Promoter holding
- 58.48%-0.85% QoQ
- FII holding
- 12.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from UltraTech Cement Ltd
All →UltraTech Cement Employee Stock Options
UltraTech Cement granted 3,536 stock options, including 3,220 Options and 316 PSUs, under its 2022 Employee Stock Option and Performance Stock Unit Scheme.
UltraTech Cement Price Movement Clarification
UltraTech Cement clarified that the recent material price movement in its shares is market-driven, confirming no undisclosed information or impending announcements triggered the movement.
UltraTech Cement Debt & Borrowing: ₹460.5 Cr
UltraTech Cement approved a corporate guarantee of up to USD 55 million (approx. ₹460.5 Crore) for UHG Holdings IFSC Private Limited to support its business operations.
- Value
- ₹460.5 Cr
UltraTech Cement Investor Presentation: Key Takeaways
UltraTech reports robust Q2FY27 performance with consolidated revenue of Rs. 23,024 Cr (+18.9% YoY) and PAT of Rs. 1,501 Cr (+21.3% YoY). The company focus remains on aggressive capacity expansion and cost control.
UltraTech Cement Debt & Borrowing: ₹522.5 Cr
UltraTech Cement's board approved a USD 55 mn (₹522.5 Cr) corporate guarantee for associate UHG Holdings IFSC. The contingent liability supports UHG Holdings' business loan.
- Value
- ₹522.5 Cr
UltraTech Cement Management Change
UltrTech Cement's Vice Chairman K.K. Maheshwari steps down w.e.f. January 2027. MD K.C. Jhanwar re-designated as Non-Executive Vice Chairman after his MD term expires.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr